Omadacycline met all FDA primary and secondary endpoints and EMA co-primary endpoints Omadacycline was generally safe and well tolerated U.S. New Drug Application planned as early as Q1 2018 Company to host a webcast and conference call for investors at 4:30 PM ET to review top-line results BOSTON, April 03, 2017 (GLOBE NEWSWIRE) — Paratek ...
The post Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia appeared first on ForexTV.
April 04, 2017 at 01:32AM
http://ift.tt/2oCIF1M
from Nasdaq NewsFeed
http://ift.tt/2oCIF1M
No comments:
Post a Comment